Discovery of a potent Gilteritinib-based FLT3-PROTAC degrader for the treatment of Acute myeloid leukemia

This publication has 22 references indexed in Scilit:

• Newly diagnosed AML: quizartinib improves OS
  Nature Reviews Clinical Oncology, 2023
• Acute myeloid leukaemia
  The Lancet, 2023
• Development of Gilteritinib-Based Chimeric Small Molecules that Potently Induce Degradation of FLT3-ITD Protein
  ACS Medicinal Chemistry Letters, 2022
• Sunitinib-based Proteolysis Targeting Chimeras (PROTACs) reduced the protein levels of FLT-3 and c-KIT in leukemia cell lines
  Bioorganic & Medicinal Chemistry Letters, 2022
• Proteolysis-Targeting Chimera (PROTAC) Modification of Dovitinib Enhances the Antiproliferative Effect against FLT3-ITD-Positive Acute Myeloid Leukemia Cells
  Journal of Medicinal Chemistry, 2021
• Gilteritinib: First Global Approval
  Drugs, 2019
• Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion
  Journal of the American Chemical Society, 2018
• The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial
  Leukemia, 2014
• Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
  Leukemia, 2012
• Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML)
  Annals of Hematology, 2011